Optas LLC Trims Position in Zoetis Inc. $ZTS

Optas LLC lessened its stake in Zoetis Inc. (NYSE:ZTS) by 19.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,010 shares of the company’s stock after selling 484 shares during the period. Optas LLC’s holdings in Zoetis were worth $313,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Nova Wealth Management Inc. purchased a new position in Zoetis in the 1st quarter worth about $25,000. 1248 Management LLC purchased a new position in Zoetis in the 1st quarter worth about $27,000. Saudi Central Bank purchased a new position in Zoetis in the 1st quarter worth about $29,000. REAP Financial Group LLC increased its stake in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares during the period. Finally, Cornerstone Planning Group LLC increased its stake in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after buying an additional 88 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.1%

Shares of Zoetis stock opened at $143.32 on Friday. The firm’s 50 day moving average price is $149.36 and its 200-day moving average price is $154.60. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $196.55. The company has a market cap of $63.52 billion, a P/E ratio of 24.67, a PEG ratio of 2.30 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the previous year, the firm earned $1.56 EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ZTS shares. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and cut their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Argus reissued a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Five research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.